{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:26:31Z","timestamp":1792628791945,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","funder":[{"DOI":"10.13039\/501100006742","name":"CESPU","doi-asserted-by":"publisher","award":["TramTap-CESPU-2016"],"award-info":[{"award-number":["TramTap-CESPU-2016"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU","doi-asserted-by":"publisher","award":["Chronic-TramTap_CESPU_2017"],"award-info":[{"award-number":["Chronic-TramTap_CESPU_2017"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU","doi-asserted-by":"publisher","award":["TraTapMDMA-CESPU-2018\""],"award-info":[{"award-number":["TraTapMDMA-CESPU-2018\""]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2019,7,29]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Mescaline (3,4,5-trimethoxyphenethylamine), mainly found in the Peyote cactus (Lophophora williamsii), is one of the oldest known hallucinogenic agents that influence human and animal behavior, but its psychoactive mechanisms remain poorly understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This article aims to fully review pharmacokinetics and pharmacodynamics of mescaline, focusing on the in vivo and in vitro metabolic profile of the drug and its implications for the variability of response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Mescaline pharmacokinetic and pharmacodynamic aspects were searched in books and in PubMed (U.S. National Library of Medicine) without a limiting period. Biological effects of other compounds found in peyote were also reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Although its illicit administration is less common, in comparison with cocaine and Cannabis, it has been extensively described in adolescents and young adults, and licit consumption often occurs in religious and therapeutic rituals practiced by the Native American Church. Its pharmacodynamic mechanisms of action are primarily attributed to the interaction with the serotonergic 5-HT2A-C receptors, and therefore clinical effects are similar to those elicited by other psychoactive substances, such as lysergic acid diethylamide (LSD) and psilocybin, which include euphoria, hallucinations, depersonalization and psychoses. Moreover, as a phenethylamine derivative, signs and symptoms are consistent with a sympathomimetic effect. Mescaline is mainly metabolized into trimethoxyphenylacetic acid by oxidative deamination but several minor metabolites with possible clinical and forensic repercussions have also been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Most reports concerning mescaline were presented in a complete absence of exposure confirmation, since toxicological analysis is not widely available. Addiction and dependence are practically absent and it is clear that most intoxications appear to be mild and are unlikely to produce lifethreatening symptoms, which favors the contemporary interest in the therapeutic potential of the drugs of the class.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874467211666181010154139","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T06:31:13Z","timestamp":1539585073000},"page":"184-194","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions"],"prefix":"10.1016","volume":"12","author":[{"given":"Ricardo Jorge","family":"Dinis-Oliveira","sequence":"first","affiliation":[{"name":"IINFACTS \u2013 Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, Rua Central de Gandra, 1317, 4585-116 Gandra PRD, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Lan\u00e7a","family":"Pereira","sequence":"additional","affiliation":[{"name":"IINFACTS \u2013 Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, Rua Central de Gandra, 1317, 4585-116 Gandra PRD, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Dias","family":"da Silva","sequence":"additional","affiliation":[{"name":"IINFACTS \u2013 Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, Rua Central de Gandra, 1317, 4585-116 Gandra PRD, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","volume":"64","author":"Bogenschutz M.P.","year":"2016","unstructured":"Bogenschutz M.P.; Johnson M.W.; Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry 2016,64,250-258","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"Nichols D.E.","year":"2004","unstructured":"Nichols D.E.; Hallucinogens. Pharmacol Ther 2004,101,131-181","journal-title":"Pharmacol Ther"},{"key":"ref=3","author":"Olive M.F.","year":"2007","unstructured":"Olive M.F.; Triggle D.J.; Drugs the straight facts: Peyote and mescaline 2007","journal-title":"Drugs the straight facts: Peyote and mescaline"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","volume":"36","author":"Lopez-Gimenez J.F.","year":"2018","unstructured":"Lopez-Gimenez J.F.; Gonzalez-Maeso J.; Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways. Curr Top Behav Neurosci 2018,36,45-73","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"Dinis-Oliveira R.J.","year":"2017","unstructured":"Dinis-Oliveira R.J.; Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metab Rev 2017,49,84-91","journal-title":"Drug Metab Rev"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2005.04.022","volume":"101","author":"El-Seedi H.R.","year":"2005","unstructured":"El-Seedi H.R.; De Smet P.A.; Beck O.; Possnert G.; Bruhn J.G.; Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol 2005,101,238-242","journal-title":"J Ethnopharmacol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","volume":"58","author":"Halpern J.H.","year":"2005","unstructured":"Halpern J.H.; Sherwood A.R.; Hudson J.I.; Yurgelun-Todd D.; Pope H.G.; Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 2005,58,624-631","journal-title":"Biol Psychiatry"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/02791072.1990.10472556","volume":"22","author":"Bullis R.K.","year":"1990","unstructured":"Bullis R.K.; Swallowing the scroll: Legal implications of the recent Supreme Court peyote cases. J Psychoactive Drugs 1990,22,325-332","journal-title":"J Psychoactive Drugs"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/NMD.0b013e3181812c68","volume":"196","author":"Csordas T.J.","year":"2008","unstructured":"Csordas T.J.; Storck M.J.; Strauss M.; Diagnosis and distress in Navajo healing. J Nerv Ment Dis 2008,196,585-596","journal-title":"J Nerv Ment Dis"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/15563650903586745","volume":"48","author":"Carstairs S.D.","year":"2010","unstructured":"Carstairs S.D.; Cantrell F.L.; Peyote and mescaline exposures: a 12-year review of a statewide poison center database. Clin Toxicol (Phila) 2010,48,350-353","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cber.18960290145","volume":"29","author":"Heffter A.","year":"1896","unstructured":"Heffter A.; Ueber Cacteenalkaloide. (II. Mittheilung). Ber Dtsch Chem Ges 1896,29,216-227","journal-title":"Ber Dtsch Chem Ges"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01524590","volume":"40","author":"Sp\u00e4th E.","year":"1919","unstructured":"Sp\u00e4th E.; \u00dcber die anhalonium-alkaloide I. Anhalin und mezcalin. Monatsh Chem 1919,40,129-154","journal-title":"Monatsh Chem"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","volume":"38","author":"Kyzar E.J.","year":"2017","unstructured":"Kyzar E.J.; Nichols C.D.; Gainetdinov R.R.; Nichols D.E.; Kalueff A.V.; Psychedelic Drugs in Biomedicine. Trends Pharmacol Sci 2017,38,992-1005","journal-title":"Trends Pharmacol Sci"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1037\/hop0000088","volume":"21","author":"Dyck E.","year":"2018","unstructured":"Dyck E.; Farrell P.; Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley. Hist Psychol 2018,21,240-253","journal-title":"Hist Psychol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/02791072.2002.10399960","volume":"34","author":"de Rios M.D.","year":"2002","unstructured":"de Rios M.D.; Grob C.S.; Baker J.R.; Hallucinogens and redemption. J Psychoactive Drugs 2002,34,239-248","journal-title":"J Psychoactive Drugs"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874473708666150107120011","volume":"7","author":"Winkelman M.","year":"2014","unstructured":"Winkelman M.; Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Curr Drug Abuse Rev 2014,7,101-116","journal-title":"Curr Drug Abuse Rev"},{"key":"ref=17","first-page":"23","volume":"30","author":"Denber H.C.","year":"1969","unstructured":"Denber H.C.; Mescaline and lysergic acid diethylamide: Therapeutic implications of the drug-induced state. Dis Nerv Syst 1969,30(Suppl.),23-27","journal-title":"Dis Nerv Syst"},{"key":"ref=18","author":"Barbosa J.","unstructured":"Barbosa J.; Faria J.; Queiros O.; Moreira R.; Carvalho F.;"},{"key":"ref=19","first-page":"14","volume":"11","author":"Dinis-Oliveira R.J.","year":"2017","unstructured":"Dinis-Oliveira R.J.; Metabolic Profile of Flunitrazepam: Clinical and Forensic Toxicological Aspects. Drug Metab Lett 2017,11,14-20","journal-title":"Drug Metab Lett"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/03602532.2017.1377223","volume":"49","author":"Dinis-Oliveira R.J.","year":"2017","unstructured":"Dinis-Oliveira R.J.; Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev 2017,49,451-463","journal-title":"Drug Metab Rev"},{"key":"ref=21","volume":"2018","author":"Dinis-Oliveira R.J.","year":"2018","unstructured":"Dinis-Oliveira R.J.; Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects. BioMed Res Int 2018,2018","journal-title":"BioMed Res Int"},{"key":"ref=22","first-page":"494","volume":"25","author":"Dinis-Oliveira R.J.","year":"2015","unstructured":"Dinis-Oliveira R.J.; Metabolomics of cocaine: Implications in toxicity. Toxicol Mech Methods 2015,25,494-500","journal-title":"Toxicol Mech Methods"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/03602532.2015.1137307","volume":"48","author":"Dinis-Oliveira R.J.","year":"2016","unstructured":"Dinis-Oliveira R.J.; Metabolomics of Delta9-tetrahydrocannabinol: Implications in toxicity. Drug Metab Rev 2016,48,80-87","journal-title":"Drug Metab Rev"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/03602532.2016.1192642","volume":"48","author":"Dinis-Oliveira R.J.","year":"2016","unstructured":"Dinis-Oliveira R.J.; Metabolomics of methadone: Clinical and forensic toxicological implications and variability of dose response. Drug Metab Rev 2016,48,568-576","journal-title":"Drug Metab Rev"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13318-016-0362-1","volume":"42","author":"Dinis-Oliveira R.J.","year":"2017","unstructured":"Dinis-Oliveira R.J.; Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects. Eur J Drug Metab Pharmacokinet 2017,42,11-16","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/03602532.2018.1448867","volume":"50","author":"Nobrega L.","year":"2018","unstructured":"Nobrega L.; Dinis-Oliveira R.J.; The synthetic cathinone alpha-pyrrolidinovalerophenone (alpha-PVP): Pharmacokinetic and pharmacodynamic clinical and forensic aspects. Drug Metab Rev 2018,50,125-139","journal-title":"Drug Metab Rev"},{"key":"ref=27","first-page":"2","volume":"2","author":"Dinis-Oliveira R.J.","year":"2017","unstructured":"Dinis-Oliveira R.J.; Metabolism and metabolomics of ketamine: A toxicological approach. J Forensic Sci 2017,2(1),2-10","journal-title":"J Forensic Sci"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jep.2010.07.021","volume":"131","author":"Ogunbodede O.","year":"2010","unstructured":"Ogunbodede O.; McCombs D.; Trout K.; Daley P.; Terry M.; New mescaline concentrations from 14 taxa\/cultivars of Echinopsis spp. (Cactaceae) (\u201cSan Pedro\u201d) and their relevance to shamanic practice. J Ethnopharmacol 2010,131,356-362","journal-title":"J Ethnopharmacol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11418-010-0469-7","volume":"65","author":"Aragane M.","year":"2011","unstructured":"Aragane M.; Sasaki Y.; Nakajima J.; Fukumori N.; Yoshizawa M.; Suzuki Y.; Kitagawa S.; Mori K.; Ogino S.; Yasuda I.; Nagumo S.; Peyote identification on the basis of differences in morphology, mescaline content, and trnL\/trnF sequence between Lophophora williamsii and L. diffusa. J Nat Med 2011,65,103-110","journal-title":"J Nat Med"},{"key":"ref=30","first-page":"489","volume":"42","author":"Carod-Artal F.J.","year":"2006","unstructured":"Carod-Artal F.J.; Vazquez-Cabrera C.B.; Mescaline and the San Pedro cactus ritual: Archaeological and ethnographic evidence in northern Peru. Rev Neurol 2006,42,489-498","journal-title":"Rev Neurol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.acc.2016.07.004","volume":"78","author":"Dasgupta A.","year":"2017","unstructured":"Dasgupta A.; Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. Adv Clin Chem 2017,78,163-186","journal-title":"Adv Clin Chem"},{"key":"ref=32","first-page":"416","volume":"36","author":"Crosby D.M.","year":"1973","unstructured":"Crosby D.M.; McLaughlin J.L.; Cactus alkaloids. XIX. Crystallization of mescaline HCl and 3-methoxytyramine HCl from Trichocereus pachanoi. Lloydia 1973,36,416-418","journal-title":"Lloydia"},{"key":"ref=33","author":"Anderson E.F.","year":"2001","unstructured":"Anderson E.F.; The cactus family 2001","journal-title":"The cactus family"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3109\/13880209.2015.1008144","volume":"53","author":"Pinto Nde C.","year":"2015","unstructured":"Pinto Nde C.; Duque A.P.; Pacheco N.R.; Mendes Rde F.; Motta E.V.; Bellozi P.M.; Ribeiro A.; Salvador M.J.; Scio E.; Pereskia aculeata: A plant food with antinociceptive activity. Pharm Biol 2015,53,1780-1785","journal-title":"Pharm Biol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3732\/ajb.1100288","volume":"99","author":"Schlumpberger B.O.","year":"2012","unstructured":"Schlumpberger B.O.; Renner S.S.; Molecular phylogenetics of Echinopsis (Cactaceae): Polyphyly at all levels and convergent evolution of pollination modes and growth forms. Am J Bot 2012,99,1335-1349","journal-title":"Am J Bot"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0031-9422(97)00240-9","volume":"46","author":"Clement B.A.","year":"1997","unstructured":"Clement B.A.; Goff C.M.; Forbes T.D.A.; Toxic amines and alkaloids from Acacia berlandieri. Phytochemistry 1997,46,249-254","journal-title":"Phytochemistry"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1126\/science.176.4039.1131","volume":"176","author":"Neal J.M.","year":"1972","unstructured":"Neal J.M.; Sato P.T.; Howald W.N.; McLaughlin J.L.; yote Alkaloids: Identification in the Mexican ictus Pelecyphora aselliformis Ehrenberg. Science 1972,176,1131-1133","journal-title":"Science"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/phar.2073","volume":"38","author":"Gomez-Coronado N.","year":"2018","unstructured":"Gomez-Coronado N.; Walker A.J.; Berk M.; Dodd S.; Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. Pharmacotherapy 2018,38,235-258","journal-title":"Pharmacotherapy"},{"key":"ref=39","first-page":"777","volume":"58","author":"Tutka P.","year":"2006","unstructured":"Tutka P.; Zatonski W.; Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 2006,58(6),777-798","journal-title":"Pharmacol Rep"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMoa1407764","volume":"371","author":"Walker N.","year":"2014","unstructured":"Walker N.; Howe C.; Glover M.; McRobbie H.; Barnes J.; Nosa V.; Parag V.; Bassett B.; Bullen C.; Cytisine versus nicotine for smoking cessation. N Engl J Med 2014,371,2353-2362","journal-title":"N Engl J Med"},{"key":"ref=41","first-page":"565","volume":"22","author":"Terry M.","year":"2006","unstructured":"Terry M.; Mauseth J.D.; Root-shoot anatomy and post-harvest vegetative clonal development in Lophophora williamsii (Cactaceae: Cacteae): Implications for conservation. 2006,22,565-592"},{"key":"ref=42","author":"Spinella M.","year":"2001","unstructured":"Spinella M.; The psychopharmacology of herbal medicine: Plant drugs that alter mind, brain, and behavior 2001","journal-title":"The psychopharmacology of herbal medicine: Plant drugs that alter mind, brain, and behavior"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/jps.2600591202","volume":"59","author":"Kapadia G.J.","year":"1970","unstructured":"Kapadia G.J.; Fayez M.B.; Peyote constituents: chemistry, biogenesis, and biological effects. J Pharm Sci 1970,59,1699-1727","journal-title":"J Pharm Sci"},{"key":"ref=44","first-page":"67","volume":"156","author":"\u0160tarha R.","year":"1996","unstructured":"\u0160tarha R.; Kuchi\u0148a J.; Analysis of Mexican Populations of Lophophora (Cactaceae). Universitas Ostraviensis Acta Facultatis Rerum Naturalium . Physica-Chemia 1996,156,67-70","journal-title":"Physica-Chemia"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01864855","volume":"34","author":"Heffter A.","year":"1894","unstructured":"Heffter A.; Ueber Pellote. Ein Betrag zur pharmakologischen Kenntnis der Cacteen. Naunyn Schmiedebergs Arch Pharmacol 1894,34,65-86","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0040-4039(01)99153-1","volume":"9","author":"Lundstrom J.","year":"1968","unstructured":"Lundstrom J.; Agurell S.; Biosynthesis of mescaline and anhalamine in peyote. IIa. Tetrahedron Lett 1968,9,4437-4440","journal-title":"Tetrahedron Lett"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2985\/026.020.0107","volume":"2015","author":"Klein M.T.","year":"2015","unstructured":"Klein M.T.; Kalam M.; Trout K.; Fowler N.; Terry M.; Mescaline concentrations in three principal tissues of Lophophora Williamsii (Cactaceae): Implications for sustainable harvesting practices. Haseltonia 2015,2015(20),34-42","journal-title":"Haseltonia"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s00216-016-9324-3","volume":"408","author":"Steiner I.","year":"2016","unstructured":"Steiner I.; Brauers G.; Temme O.; Daldrup T.; A sensitive method for the determination of hordenine in human serum by ESI(+) UPLC-MS\/MS for forensic toxicological applications. Anal Bioanal Chem 2016,408,2285-2292","journal-title":"Anal Bioanal Chem"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.2042-3306.1990.tb04312.x","volume":"22","author":"Frank M.","year":"1990","unstructured":"Frank M.; Weckman T.J.; Wood T.; Woods W.E.; Tai C.L.; Chang S.L.; Ewing A.; Blake J.W.; Tobin T.; Hordenine: Pharmacology, pharmacokinetics and behavioural effects in the horse. Equine Vet J 1990,22,437-441","journal-title":"Equine Vet J"},{"key":"ref=50","first-page":"169","volume":"32","author":"Ghansah E.","year":"1993","unstructured":"Ghansah E.; Kopsombut P.; Maleque M.A.; Brossi A.; Effects of mescaline and some of its analogs on cholinergic neuromuscular transmission. Neuropsychopharmacol 1993,32,169-174","journal-title":"Neuropsychopharmacol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/02791072.2008.10400635","volume":"40","author":"Bruhn J.G.","year":"2008","unstructured":"Bruhn J.G.; El-Seedi H.R.; Stephanson N.; Beck O.; Shulgin A.T.; Ecstasy analogues found in cacti. J Psychoactive Drugs 2008,40,219-222","journal-title":"J Psychoactive Drugs"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jat.2885","volume":"34","author":"da Silva D.D.","year":"2014","unstructured":"da Silva D.D.; Silva E.; Carvalho F.; Carmo H.; Mixtures of 3,4-methylenedioxymethamphetamine (ecstasy) and its major human metabolites act additively to induce significant toxicity to liver cells when combined at low, non-cytotoxic concentrations. J Appl Toxicol 2014,34,618-627","journal-title":"J Appl Toxicol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tips.2008.06.007","volume":"29","author":"Millan M.J.","year":"2008","unstructured":"Millan M.J.; Marin P.; Bockaert J.; Mannoury la Cour C.; Signaling at G-protein-coupled serotonin receptors: Recent advances and future research directions. Trends Pharmacol Sci 2008,29,454-464","journal-title":"Trends Pharmacol Sci"},{"key":"ref=54","first-page":"1795","volume":"29","author":"Landolt H.P.","year":"2009","unstructured":"Landolt H.P.; Wehrle R.; Antagonism of serotonergic 5-HT2A\/2C receptors: Mutual improvement of sleep, cognition and mood? Eur J Neurol 2009,29,1795-1809","journal-title":"Eur J Neurol"},{"key":"ref=55","doi-asserted-by":"crossref","DOI":"10.1002\/9783527673643","author":"Urb\u00e1n L.","year":"2015","unstructured":"Urb\u00e1n L.; Patel V.F.; Vaz R.J.; Antitargets and drug safety 2015","journal-title":"Antitargets and drug safety"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"16s","DOI":"10.1016\/S0893-133X(98)00135-3","volume":"21","author":"Aghajanian G.K.","year":"1999","unstructured":"Aghajanian G.K.; Marek G.J.; Serotonin and hallucinogens. Neuropsychopharmacology 1999,21,16s-23s","journal-title":"Neuropsychopharmacology"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1021\/jm970219x","volume":"40","author":"Monte A.P.","year":"1997","unstructured":"Monte A.P.; Waldman S.R.; Marona-Lewicka D.; Wainscott D.B.; Nelson D.L.; Sanders-Bush E.; Nichols D.E.; Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 1997,40,2997-3008","journal-title":"J Med Chem"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0006-2952(70)90378-3","volume":"19","author":"Freedman D.X.","year":"1970","unstructured":"Freedman D.X.; Gottlieb R.; Lovell R.A.; Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism. Biochem Pharmacol 1970,19,1181-1188","journal-title":"Biochem Pharmacol"},{"key":"ref=59","first-page":"387","volume":"181","author":"Tilson H.A.","year":"1972","unstructured":"Tilson H.A.; Sparber S.B.; Studies on the concurrent behavioral and neurochemical effects of psychoactive drugs using the push-pull cannula. J Pharmacol Exp Ther 1972,181,387-398","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-2999(83)90544-7","volume":"96","author":"Trulson M.E.","year":"1983","unstructured":"Trulson M.E.; Crisp T.; Henderson L.J.; Mescaline elicits behavioral effects in cats by an action at both serotonin and dopamine receptors. Eur J Pharmacol 1983,96,151-154","journal-title":"Eur J Pharmacol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.me.20.020169.002205","volume":"20","author":"Freedman D.X.","year":"1969","unstructured":"Freedman D.X.; The psychopharmacology of hallucinogenic agents. Annu Rev Med 1969,20,409-418","journal-title":"Annu Rev Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","volume":"59","author":"van Amsterdam J.","year":"2011","unstructured":"van Amsterdam J.; Opperhuizen A.; van den Brink W.; Harm potential of magic mush2room use: A review. Regul Toxicol Pharmacol 2011,59,423-429","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref=63","first-page":"63","volume":"78","author":"Dasgupta A.","year":"2017","unstructured":"Dasgupta A.; Chapter Five - Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. Advances in clinical chemistry, Makowski, 2017,78,63-186","journal-title":"Advances in clinical chemistry, Makowski,"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00005053-195908000-00007","volume":"129","author":"Mokrasch L.C.","year":"1959","unstructured":"Mokrasch L.C.; Stevenson I.; The metabolism of mescaline with a note on correlations between metabolism and psychological effects. J Nerv Ment Dis 1959,129,177-183","journal-title":"J Nerv Ment Dis"},{"key":"ref=65","first-page":"205","volume":"101","author":"Cochin J.","year":"1951","unstructured":"Cochin J.; Woods L.A.; Seevers M.H.; The absorption, distribution and urinary excretion of mescaline in the dog. J Pharmacol Exp Ther 1951,101,205-209","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-007-0926-5","volume":"196","author":"Palenicek T.","year":"2008","unstructured":"Palenicek T.; Balikova M.; Bubenikova-Valesova V.; Horacek J.; Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacology 2008,196,51-62","journal-title":"Psychopharmacology"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2004.03.003","volume":"102","author":"Halpern J.H.","year":"2004","unstructured":"Halpern J.H.; Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 2004,102,131-138","journal-title":"Pharmacol Ther"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF00427703","volume":"9","author":"Charalampous K.D.","year":"1966","unstructured":"Charalampous K.D.; Walker K.E.; Kinross-Wright J.; Metabolic fate of mescaline in man. Psychopharmacology 1966,9,48-63","journal-title":"Psychopharmacology"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000105047","volume":"18","author":"Harley-Mason J.","year":"1958","unstructured":"Harley-Mason J.; Laird A.H.; Smythies J.R.; The metabolism of mescalin in the human; Delayed clinical reactions to mescalin. Confin Neurol 1958,18,152-155","journal-title":"Confin Neurol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0014-2999(73)90159-3","volume":"24","author":"Shah N.S.","year":"1973","unstructured":"Shah N.S.; Green C.; Tissue levels of mescaline in mice: Influence of chlorpromazine on repeated administration of mescaline. Eur J Pharmacol 1973,24,334-340","journal-title":"Eur J Pharmacol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0006-2952(74)90417-1","volume":"23","author":"Seiler N.","year":"1974","unstructured":"Seiler N.; Demisch L.; Oxidative metabolism of mescaline in the central nervous system-III: Side chain degradation of mescaline and formation of 3,4,5-trimethoxy-benzoic acid In vivo. Biochem Pharmacol 1974,23,259-271","journal-title":"Biochem Pharmacol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1749-6632.1962.tb50099.x","volume":"96","author":"Daly J.","year":"1962","unstructured":"Daly J.; Axelrod J.; Witkop B.; Methylation and demethylation in relation to the in vitro metabolism of mescaline. Ann N Y Acad Sci 1962,96,37-43","journal-title":"Ann N Y Acad Sci"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4161\/oxim.2.4.9380","volume":"2","author":"Kovacic P.","year":"2009","unstructured":"Kovacic P.; Somanathan R.; Novel, unifying mechanism for mescaline in the central nervous system: Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships. Oxid Med Cell Longev 2009,2,181-190","journal-title":"Oxid Med Cell Longev"},{"key":"ref=74","first-page":"547","volume":"10","author":"Shah N.S.","year":"1971","unstructured":"Shah N.S.; Himwich H.E.; Study with mescaline-8-C14 in mice: Effect of amine oxidase inhibitors on metabolism. Neuropsychopharmacol 1971,10,547-556","journal-title":"Neuropsychopharmacol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0006-2952(80)90337-8","volume":"29","author":"Hilliker K.S.","year":"1980","unstructured":"Hilliker K.S.; Roth R.A.; Prediction of mescaline clearance by rabbit lung and liver from enzyme kinetic data. Biochem Pharmacol 1980,29,253-255","journal-title":"Biochem Pharmacol"},{"key":"ref=76","doi-asserted-by":"crossref","DOI":"10.1201\/9780203712504","author":"Scheline R.R.","year":"2017","unstructured":"Scheline R.R.; Handbook of mammalian metabolism of plant compounds (1991) 2017","journal-title":"Handbook of mammalian metabolism of plant compounds (1991)"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1749-6632.1962.tb50097.x","volume":"96","author":"Friedhoff A.J.","year":"1962","unstructured":"Friedhoff A.J.; Goldstein M.; New developments in metabolism of mescaline and related amines. Ann N Y Acad Sci 1962,96,5-13","journal-title":"Ann N Y Acad Sci"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/0006-2952(71)90249-8","volume":"20","author":"Seiler N.","year":"1971","unstructured":"Seiler N.; Demisch L.; Oxidative metabolism of mescaline in the central nervous system. II. Oxidative deamination of mescaline and 2,3,4-trimethoxy-beta-phenylethylamine by different mouse brain area in vitro. Biochem Pharmacol 1971,20,2485-2493","journal-title":"Biochem Pharmacol"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1748-1716.1947.tb00471.x","volume":"14","author":"Steensholt G.","year":"1947","unstructured":"Steensholt G.; On an amine oxidase in rabbit\u2019s liver. Acta Physiol Scand 1947,14,356-362","journal-title":"Acta Physiol Scand"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0006-2952(75)90176-8","volume":"24","author":"Demisch L.","year":"1975","unstructured":"Demisch L.; Seiler N.; Oxidative metabolism of mescaline in the central nervous system-V: In vitro deamination of mescaline to 3,4,5-trimethoxy-benzoic acid. Biochem Pharmacol 1975,24,575-580","journal-title":"Biochem Pharmacol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00204-012-0815-5","volume":"86","author":"Carvalho M.","year":"2012","unstructured":"Carvalho M.; Carmo H.; Costa V.M.; Capela J.P.; Pontes H.; Remiao F.; Carvalho F.; Bastos Mde L.; Toxicity of amphetamines: An update. Arch Toxicol 2012,86,1167-1231","journal-title":"Arch Toxicol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0006-2952(75)90176-8","volume":"24","author":"Demisch L.","year":"1975","unstructured":"Demisch L.; Seiler N.; Oxidative metabolism of mescaline in the central nervous system-V. In vitro deamination of mescaline to 3,4,5-trimethoxy-benzoic acid. Biochem Pharmacol 1975,24,575-580","journal-title":"Biochem Pharmacol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0006-2952(67)90268-7","volume":"16","author":"Musacchio J.","year":"1967","unstructured":"Musacchio J.; Goldstein M.; The metabolism of mescaline-14C in rats. Biochem Pharmacol 1967,16,963-970","journal-title":"Biochem Pharmacol"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1042\/bj0630634","volume":"63","author":"Axelrod J.","year":"1956","unstructured":"Axelrod J.; The enzymic cleavage of aromatic ethers. Biochem J 1956,63,634-639","journal-title":"Biochem J"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0006-2952(66)90298-X","volume":"15","author":"Friedhoff A.J.","year":"1966","unstructured":"Friedhoff A.J.; Hollister L.E.; Comparison of the metabolism of 3,4-dimethoxyphenylethylamine and mescaline in humans. Biochem Pharmacol 1966,15,269-273","journal-title":"Biochem Pharmacol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0006-2952(97)00014-2","volume":"53","author":"Wu D.","year":"1997","unstructured":"Wu D.; Otton S.V.; Inaba T.; Kalow W.; Sellers E.M.; Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997,53,1605-1612","journal-title":"Biochem Pharmacol"},{"key":"ref=87","first-page":"507","volume":"6","author":"Demisch L.","year":"1978","unstructured":"Demisch L.; Kaczmarczyk P.; Seiler N.; 3,4,5-Trimethoxybenzoic acid, a new mescaline metabolite in humans. Drug Metab Dispos 1978,6,507-509","journal-title":"Drug Metab Dispos"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/S0021-9258(19)73955-6","volume":"237","author":"Goldstein M.","year":"1962","unstructured":"Goldstein M.; Contrera J.F.; The substrate specificity of phenylamine-beta-hydroxylase. J Biol Chem 1962,237,1898-1902","journal-title":"J Biol Chem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0006-3223(92)90059-9","volume":"32","author":"Hermle L.","year":"1992","unstructured":"Hermle L.; Funfgeld M.; Oepen G.; Botsch H.; Borchardt D.; Gouzoulis E.; Fehrenbach R.A.; Spitzer M.; Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992,32,976-991","journal-title":"Biol Psychiatry"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0041-008X(73)80016-X","volume":"25","author":"Hardman H.F.","year":"1973","unstructured":"Hardman H.F.; Haavik C.O.; Seevers M.H.; Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 1973,25,299-309","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.163.3864.245","volume":"163","author":"Schultes R.E.","year":"1969","unstructured":"Schultes R.E.; Hallucinogens of plant origin. Science 1969,163,245-254","journal-title":"Science"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1162\/089976602317250861","volume":"14","author":"Bressloff P.C.","year":"2002","unstructured":"Bressloff P.C.; Cowan J.D.; Golubitsky M.; Thomas P.J.; Wiener M.C.; What geometric visual hallucinations tell us about the visual cortex. Neural Comput 2002,14,473-491","journal-title":"Neural Comput"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12640-015-9569-1","volume":"29","author":"Golembiowska K.","year":"2016","unstructured":"Golembiowska K.; Jurczak A.; Kaminska K.; Noworyta-Sokolowska K.; Gorska A.; Effect of Some Psychoactive Drugs Used as \u2018Legal Highs\u2019 on Brain Neurotransmitters. Neurotox Res 2016,29,394-407","journal-title":"Neurotox Res"},{"key":"ref=94","first-page":"46","volume":"36","author":"Shulgin A.T.","year":"1973","unstructured":"Shulgin A.T.; Mescaline: The chemistry and pharmacology of its analogs. Lloydia 1973,36,46-58","journal-title":"Lloydia"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1525\/aa.1938.40.4.02a00100","volume":"40","author":"Schultes R.E.","year":"1938","unstructured":"Schultes R.E.; The Appeal of Peyote (Lophophora Williamsii) as a Medicine. Am Anthropol 1938,40,698-715","journal-title":"Am Anthropol"},{"key":"ref=96","first-page":"1","volume":"36","author":"McLaughlin J.L.","year":"1973","unstructured":"McLaughlin J.L.; Peyote: An introduction. Lloydia 1973,36,1-8","journal-title":"Lloydia"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/16066359609010756","volume":"4","author":"Halpern J.H.","year":"1996","unstructured":"Halpern J.H.; The Use of Hallucinogens in the Treatment of Addiction. Addict Res 1996,4,177-189","journal-title":"Addict Res"},{"key":"ref=98","first-page":"27","volume":"54","author":"Gilmore H.T.","year":"2001","unstructured":"Gilmore H.T.; Peyote use during pregnancy. S D J Med 2001,54,27-29","journal-title":"S D J Med"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.chc.2016.03.006","volume":"25","author":"Hardaway R.","year":"2016","unstructured":"Hardaway R.; Schweitzer J.; Suzuki J.; Hallucinogen Use Disorders. Child Adolesc Psychiatr Clin N Am 2016,25,489-496","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0031-3955(16)36219-8","volume":"34","author":"Brown R.T.","year":"1987","unstructured":"Brown R.T.; Braden N.J.; Hallucinogens. Pediatr Clin North Am 1987,34,341-347","journal-title":"Pediatr Clin North Am"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1176\/ajp.114.11.1038","volume":"114","author":"Stevenson I.","year":"1958","unstructured":"Stevenson I.; Mokrasch L.C.; A further note on the mechanism of the antidotal action of sodium succinate in the mescaline psychosis. Am J Psychiatry 1958,114,1038-1039","journal-title":"Am J Psychiatry"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1176\/ajp.114.4.328","volume":"114","author":"Stevenson I.","year":"1957","unstructured":"Stevenson I.; Sanchez A.J.; The antidotal action of sodium succinate in the mescaline psychosis. Am J Psychiatry 1957,114,328-332","journal-title":"Am J Psychiatry"},{"key":"ref=103","first-page":"328","volume":"170","author":"Nolte K.B.","year":"1999","unstructured":"Nolte K.B.; Zumwalt R.E.; Fatal peyote ingestion associated with Mallory-Weiss lacerations. West J Med 1999,170,328","journal-title":"West J Med"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJM199807163390316","volume":"339","author":"Hashimoto H.","year":"1998","unstructured":"Hashimoto H.; Clyde V.J.; Parko K.L.; Botulism from peyote. N Engl J Med 1998,339,203-204","journal-title":"N Engl J Med"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF02907956","volume":"14","author":"McCleary J.A.","year":"1960","unstructured":"McCleary J.A.; Sypherd P.S.; Walkington D.L.; Antibiotic activity of an extract of peyote (Lophophora Williamii (Lemaire) coulter). Econ Bot 1960,14,247-249","journal-title":"Econ Bot"},{"key":"ref=106","author":"Lumholtz C.","year":"1903","unstructured":"Lumholtz C.; Unknown Mexico 1903","journal-title":"Unknown Mexico"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acschemneuro.8b00215","volume":"9","author":"Cassels B.K.","year":"2018","unstructured":"Cassels B.K.; Saez-Briones P.; Dark classics in chemical neuroscience: mescaline. ACS Chem Neurosci 2018,9(10),2448-2458","journal-title":"ACS Chem Neurosci"},{"key":"ref=108","first-page":"200","volume":"142","author":"Rucker J.J.H.","year":"2017","unstructured":"Rucker J.J.H.; Iliff J.; Nutt D.; J. Psychiatry","journal-title":"Neuropsychopharmacol"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"Rickli A.","year":"2016","unstructured":"Rickli A.; Moning O.D.; Hoener M.C.; Liechti M.E.; Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 2016,26,1327-1337","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=110","author":"Shulgin A.T.","year":"1991","unstructured":"Shulgin A.T.; Shulgin A.; PIHKAL: A chemical love story 1991","journal-title":"PIHKAL: A chemical love story"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/166140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:56:41Z","timestamp":1746572201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/166140\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467211666181010154139","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}